Dimed Distribuidora de Medicamentos Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Dimed Distribuidora de Medicamentos kazanç ve gelirin sırasıyla yıllık 23.4% ve 10.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 27% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 13.6% olacağı tahmin edilmektedir.

Anahtar bilgiler

23.4%

Kazanç büyüme oranı

27.0%

EPS büyüme oranı

Consumer Retailing kazanç büyümesi	29.9%
Gelir büyüme oranı	10.8%
Gelecekteki özkaynak getirisi	13.6%
Analist kapsamı	Low
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15

Kazanç ve Gelir Büyüme Tahminleri

BOVESPA:PNVL3 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (BRL Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	6,391	187	19	314	5
12/31/2025	5,702	145	-33	272	5
12/31/2024	5,151	122	6	322	2
9/30/2024	4,818	104	125	274	N/A
6/30/2024	4,712	91	190	321	N/A
3/31/2024	4,660	108	178	313	N/A
12/31/2023	4,461	93	157	297	N/A
9/30/2023	4,325	88	144	282	N/A
6/30/2023	4,211	83	175	325	N/A
3/31/2023	4,116	84	69	228	N/A
12/31/2022	3,990	86	24	205	N/A
9/30/2022	3,799	85	17	198	N/A
6/30/2022	3,584	83	21	189	N/A
3/31/2022	3,375	80	15	175	N/A
12/31/2021	3,225	79	-4	131	N/A
9/30/2021	3,135	79	-56	78	N/A
6/30/2021	3,032	79	-58	63	N/A
3/31/2021	2,878	62	-41	57	N/A
12/31/2020	2,819	56	46	131	N/A
9/30/2020	2,764	56	82	147	N/A
6/30/2020	2,754	62	34	90	N/A
3/31/2020	2,780	78	73	133	N/A
12/31/2019	2,725	77	75	129	N/A
9/30/2019	2,638	80	89	131	N/A
6/30/2019	2,562	79	65	106	N/A
3/31/2019	2,500	76	72	117	N/A
12/31/2018	2,432	75	51	110	N/A
9/30/2018	2,359	65	-20	45	N/A
6/30/2018	2,317	59	N/A	62	N/A
3/31/2018	2,282	59	N/A	29	N/A
12/31/2017	2,258	60	N/A	41	N/A
9/30/2017	2,238	60	N/A	78	N/A
6/30/2017	2,191	59	N/A	68	N/A
3/31/2017	2,146	57	N/A	104	N/A
12/31/2016	2,129	53	N/A	102	N/A
9/30/2016	2,095	53	N/A	92	N/A
6/30/2016	2,074	50	N/A	93	N/A
3/31/2016	2,043	50	N/A	76	N/A
12/31/2015	1,986	45	N/A	73	N/A
9/30/2015	1,963	44	N/A	59	N/A
6/30/2015	1,927	43	N/A	56	N/A
3/31/2015	1,916	48	N/A	26	N/A
12/31/2014	1,887	49	N/A	23	N/A
9/30/2014	1,835	50	N/A	29	N/A
6/30/2014	1,823	58	N/A	50	N/A
3/31/2014	1,786	55	N/A	66	N/A
12/31/2013	1,740	56	N/A	62	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: PNVL3 'nin tahmini kazanç büyümesi (yıllık 23.4% ) tasarruf oranının ( 10.4% ) üzerindedir.

Kazançlar ve Piyasa: PNVL3 şirketinin kazançlarının (yıllık 23.4% ) BR pazarından (yıllık 12.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: PNVL3 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.

Gelir ve Pazar: PNVL3 şirketinin gelirinin (yıllık 10.8% ) BR pazarından (yıllık 7.4% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: PNVL3 şirketinin gelirinin (yıllık 10.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: PNVL3 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 13.6 %).

Dimed Distribuidora de Medicamentos Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Third quarter 2024 earnings released: EPS: R$0.24 (vs R$0.16 in 3Q 2023)

Second quarter 2024 earnings released: EPS: R$0.034 (vs R$0.15 in 2Q 2023)

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.12 in 1Q 2023)

Full year 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of R$0.068 per share at 1.9% yield

Third quarter 2023 earnings released: EPS: R$0.16 (vs R$0.12 in 3Q 2022)

Upcoming dividend of R$0.046 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: R$0.15 (vs R$0.16 in 2Q 2022)

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Full year 2022 earnings released: EPS: R$0.58 (vs R$0.53 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Second quarter 2022 earnings released

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

First quarter 2022 earnings: Revenues exceed analyst expectations

Price target decreased to R$22.85

No independent directors

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Full year 2021 earnings: EPS misses analyst expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorated over the past week

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Price target decreased to R$30.20

Third quarter 2021 earnings released

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorated over the past week

Upcoming dividend of R$0.034 per share

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Dimed S.A. Distribuidora de Medicamentos(BOVESPA:PNVL4) dropped from Brazil Special Tag Along Stock Index

Dimed S.A. Distribuidora de Medicamentos announced that it expects to receive funding from Kinea Private Equity Investimentos S.A.

Dimed S.A. Distribuidora de Medicamentos has completed a Follow-on Equity Offering in the amount of BRL 1.036713 billion.

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin